TruGolf Holdingsの空売り状況は、投資家がTruGolf Holdingsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

TruGolf Holdings (NASDAQ:TRUG) 株価情報, 空売り情報

TruGolf Holdings

TruGolf Holdings Inc is a indoor golf gaming solutions company. It has built video games ("Links"), innovative hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6 CONNECT.

TruGolf Holdings, Inc. - Class A Common Stock

TruGolf Holdings Inc

TRUGOLF HLDGS INC RT

Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) chief Hock Tan expressed enormous conviction over the sustainability of the <a target="_blank" href="https://www.benzinga.com/topic/ai" rel="noreferrer noopener">artificial intelligence frenzy</a> as Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google, Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and TikTok parent ByteDance splurged on designing custom processors that accelerate training and deployment of AI systems, the Financial Times reports.
Reportedly, OpenAI and Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) also tapped Broadcom to develop their AI server chips to diversify their exposure to Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
Broadcom stock has surged over 101% year-to-date.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/downgrades/24/12/42561430/match-group-analyst-flags-tinder-woes-industry-challenges-for-stock-downgrade" rel="noreferrer noopener">Match Group Analyst Flags Tinder Woes, Industry Challenges For Stock Downgrade</a>
Tan <a target="_blank" href="https://www.ft.com/content/5b4160b7-6920-4bf2-a1a8-f1404b513d8f" rel="noreferrer noopener">told</a> FT that he expected the demand to continue for at least ten years, citing their enormous return potential.
Tan stressed to the FT that clients were intensely ramping up AI infrastructure investment plans spanning three to five years.
He does not expect the phenomenon to lose steam until his clients run out of finances.
Last week, Tan told investors Broadcom <a target="_blank" href="https://www.benzinga.com//node/42488220" rel="noreferrer noopener">could generate</a> tens of billions of dollars in additional annual revenue from AI chips by 2027.
Tan&#8217;s experience and dealmaking prowess fuelled speculation of rescuing struggling chipmaker Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>). However, Tan claimed no hostile offers since 2018, when it was tracking Qualcomm Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), which succumbed to regulatory opposition.
Tan backed his thesis by citing investments by OpenAI and Elon Musk&#8217;s xAI in data centers in 2024.
Tan told the FT that its customers will build clusters of up to 1 million AI chips by 2027. However, Tan said that even 1 million chips may not suffice the AI ambitions of OpenAI and Anthropic.
Broadcom&#8217;s stock price rallied 24% in a single day last Friday after its AI revenues had surged by 220% in fiscal 2024. The chipmaker added over $200 billion to its market cap, breaching the $1 trillion milestone for the first time.
Rosenblatt&#8217;s Hans Mosesmann&nbsp;expects <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42489281/broadcoms-ai-chip-leadership-puts-pressure-on-nvidia-and-marvell-analysts-say" rel="noreferrer noopener">Broadcom&#8217;s growing moat</a> in expanding custom-chip (ASIC) AI and surging AI opportunities to intensify the rivalry with Advanced Micro Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) and Nvidia. B of A Securities&#8216; Vivek Arya&nbsp;credited Broadcom with maintaining a position at customer Apple.
Investors can gain exposure to Broadcom through Amplify ETF Trust Amplify Cybersecurity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HACK#NYSE">HACK</a>) and First Trust NASDAQ Technology Dividend Index Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDIV#NASDAQ">TDIV</a>).
Price Action:&nbsp;AVGO stock closed lower by 2.37% at $218.32 Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42561240/salesforces-ai-powered-agentforce-20-spurs-analyst-upgrades-and-growth-optimism" target="_blank" rel="noreferrer noopener">Wall Street Analysts Are Bullish On Salesforce&#8217;s AI Vision &#8211; Here&#8217;s Why</a></li>
</ul>
Photo via Shutterstock

News

Movers

Tech

Media

Trading Ideas

AAPL

AVGO

GOOG

GOOGL

HACK

INTC

NVDA

QCOM

TDIV

Broadcom Expects Decade-Long AI Chip Boom as Big Tech Invest Billions

HC Wainwright &amp; Co. analyst Yi Chen reiterates Veru (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERU#NASDAQ">VERU</a>) with a Buy and maintains $3 price target.

Price Target

Reiteration

Analyst Ratings

VERU

HC Wainwright & Co. Reiterates Buy on Veru, Maintains $3 Price Target

ALSA

Alpha Star Acquisition Corporation Reveals Receipt Of Letter From Nasdaq Regarding Failure To Complete Initial Business Combination

Offerings

ENGN

Engene Holdings Said Entered Into Open Market Sale Agreement, May Offer & Sell Common Shares Of Up To $100M

VRCA

Verrica Provides Business And Operational Update: Says Dispensed Applicator Units In Q4 Have Exceeded Complete Prior Quarter Even With Significant Cost Reductions In Sales And Operational Infrastructure, Observed Significant Reduction In Ycanth Distributor Inventory Levels

The Company has issued a Worker Adjustment and Retraining Notification&nbsp;Act (WARN Act) notice (the Notice) to its employees at the Company's Bolingbrook, Illinois and Troy, Michigan facilities, as well as to substantially all of its remaining employees in the states of Illinois and Michigan.&nbsp;
Hyzon cited its inability to raise funding and the future uncertainty relating to the availability of government subsidies, most notably the California Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project, which the Company believes has caused certain of its customers to slow down or suspend their purchasing decisions.
If the Company cannot raise funds or find a buyer, it is expected that the reduction in force will be completed in February 2025.

HYZN

Hyzon Issues Worker Adjustment And Retraining Notification, Citing Its Inability To Raise Funding And The Future Uncertainty Relating To Availability Of Government Subsidies

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Buy and lowers the price target from $84 to $48.

PRTA

HC Wainwright & Co. Reiterates Buy on Prothena Corp, Lowers Price Target to $48

Guidance

Winnebago Industries Sees FY25 Revenues Of $2.9B-$3.2B Vs. $2.99B Estimate, Projects Adjusted Eps Of $3.10-$4.40 Vs. $3.39 Estimate (Compared With A Prior Range Of $3.00-$4.50)

The seven-year agreement strengthens Air Industries' pivotal role in supporting one of the U.S. Department of Defense's most important procurement programs.

Contracts

AIRI

Air Industries Secures Long-term Contract Valued At More Than $33M To Manufacture, Supply Complex Components For CH-53K King Stallion Helicopter Program

Rosenblatt analyst Kevin Cassidy upgrades Innoviz Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVZ#NASDAQ">INVZ</a>) from Neutral to Buy and raises the price target from $3.25 to $4.

Upgrades

INVZ

Rosenblatt Upgrades Innoviz Technologies to Buy, Raises Price Target to $4

<a href="https://www.globenewswire.com/Tracker?data=Myv-69gOUCJgo4iWs3nsz31ZPczO7ocKKHfzl4XL1e1L9RkdUKQibBVRmpixUEREcIgnv9SO7KnFXgpTtMfCRw==">Silvaco Group, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>), a provider of TCAD, EDA software and SIP solutions that enable semiconductor design and digital twin modeling through AI software and innovation, today announced a strategic sales partnership with <a href="https://www.globenewswire.com/Tracker?data=r59takPzEK4CVfOOZ6LI-kaTEo9oZxfJ2pa2N0-vWDB0w4FefKTfo_XE83yqW-CLiVzP2weInfF_itKp1KGV4WZvgklawtOGvXVXUZHsjUQ=">Micon Global.</a> The partnership between&nbsp;Silvaco&nbsp;and&nbsp;Micon Global&nbsp;is expected to drive&nbsp;Silvaco's expansion across the EMEA market, leveraging&nbsp;Micon Global's expertise to enhance client access to&nbsp;Silvaco's design solutions.

SVCO

Silvaco Partners With Micon Global to Boost Semiconductor Solutions in EMEA

"We have already taken steps to address all concerns raised by the CMA after their Phase 1 investigation. For example, Synopsys previously announced plans to sell its Optical Solutions business to Keysight, subject to the closing of Synopsys' proposed acquisition of Ansys," the company said.

ANSS

SNPS

Synopsys Responds To UK CMA's Phase 1 Announcement Regarding Ansys Acquisition; Continues To Express Support For The Transaction

CCC Intelligent Solutions Holdings Inc. (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCS#NASDAQ">CCCS</a>), a leading cloud platform provider for the P&amp;C insurance economy, today announced that its board of directors has approved a new share repurchase authorization to repurchase up to $300 million of the Company's outstanding common stock.
Under the repurchase authorization, the Company is authorized to repurchase shares through open market purchases, privately negotiated transactions, or accelerated share repurchases. The repurchase authorization does not obligate the Company to repurchase shares and the specific timing and amount of repurchases may vary based on available capital resources, market conditions, management's discretion, securities law limitations, and other factors. Repurchases, if any, will be funded out of available liquidity and free cash flow.

Buybacks

CCCS

CCC Intelligent Solutions Board Approved Fresh $300M Share Buyback

Winnebago Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $0.20 by 115 percent. The company reported quarterly sales of $625.600 million which missed the analyst consensus estimate of $672.232 million by 6.94 percent. This is a 18.01 percent decrease over sales of $763.000 million the same period last year.

Earnings

Earnings Misses

Winnebago Industries Q1 2025 Adj. EPS $(0.03) Misses $0.20 Estimate, Sales $625.600M Miss $672.232M Estimate

ECARX Holdings Plans Repurchase Of Up To $20M Of Its Ordinary Shares Until  Close Of Business On September 30, 2025

Management

APLT

Applied Therapeutics Names John H. Johnson As Executive Chairman; Shoshana Shendelman Has Stepped Down As Chair And CEO; Les Funtleyder Named As Interim CEO

Chardan Capital analyst Rudy Li initiates coverage on Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Buy rating and announces Price Target of $40.

Initiation

Chardan Capital Initiates Coverage On Prothena Corp with Buy Rating, Announces Price Target of $40

Across the recent three months, 5 analysts have shared their insights on Evercore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVR#NYSE">EVR</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $307.2, a high estimate of $339.00, and a low estimate of $265.00. This current average has increased by 12.2% from the previous average price target of $273.80. 
<img src="https://www.benzinga.com/files/images/story/2024/1734696055_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Evercore by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$339.00</td>
<td>$269.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$318.00</td>
<td>$266.00</td>
</tr>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$308.00</td>
<td>$306.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$265.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Ryan Kenny</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$306.00</td>
<td>$273.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Evercore. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Evercore compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Evercore's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Evercore's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EVR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Evercore analyst ratings.</a>
<h2>All You Need to Know About Evercore</h2>
Evercore is an independent investment bank that derives the majority of its revenue from financial advisory, including merger, acquisition, and restructuring advisory. It also has institutional equities trading, equity underwriting, and investment management businesses that account for around 20% of net revenue. The company was founded in 1996 and went public in 2006. Evercore had approximately 2,200 employees at the end of 2023, and about 75% of its revenue is derived from the United States.
<h3>Evercore: Delving into Financials</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Evercore's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 28.76%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 10.68%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Evercore's ROE stands out, surpassing industry averages. With an impressive ROE of 5.1%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Evercore's ROA excels beyond industry benchmarks, reaching 2.28%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.55, Evercore adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Evercore: 5 Analysts Share Their Views

Throughout the last three months, 8 analysts have evaluated Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Avidity Biosciences, revealing an average target of $65.75, a high estimate of $78.00, and a low estimate of $59.00. Witnessing a positive shift, the current average has risen by 9.22% from the previous average price target of $60.20.
<img src="https://www.benzinga.com/files/images/story/2024/1734696047_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive Avidity Biosciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$72.00</td>
<td>-</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$67.00</td>
<td>-</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$78.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Corinne Johnson</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$59.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Avidity Biosciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Avidity Biosciences compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Avidity Biosciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Avidity Biosciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/RNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Avidity Biosciences analyst ratings.</a>
<h2>About Avidity Biosciences</h2>
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
<h3>Financial Milestones: Avidity Biosciences's Journey</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Decline in Revenue: Over the 3 months period, Avidity Biosciences faced challenges, resulting in a decline of approximately -17.1% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Avidity Biosciences's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -3441.7%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Avidity Biosciences's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -5.9%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Avidity Biosciences's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -5.38%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.01, Avidity Biosciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 8 Analyst Ratings Have To Say About Avidity Biosciences

In the preceding three months, 16 analysts have released ratings for Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">14</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Dollar Tree and provided 12-month price targets. The average target is $78.81, accompanied by a high estimate of $100.00 and a low estimate of $65.00. Experiencing a 0.78% decline, the current average is now lower than the previous average price target of $79.43. 
<img src="https://www.benzinga.com/files/images/story/2024/1734696039_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Dollar Tree among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>John Heinbockel</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Hold</td>
<td>$75.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$70.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$83.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$76.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$72.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Daniel Binder</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$92.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$65.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$82.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$75.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$100.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Brandon Fletcher</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$76.00</td>
<td>-</td>
</tr>
<tr>
<td>Karen Short</td>
<td>Melius Research</td>
<td>Announces</td>
<td>Hold</td>
<td>$70.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dollar Tree. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dollar Tree compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Dollar Tree's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Dollar Tree's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DLTR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Dollar Tree analyst ratings.</a>
<h2>Get to Know Dollar Tree Better</h2>
Dollar Tree operates discount stores across the United States and Canada, with over 8,600 shops under its namesake banner and nearly 7,800 under Family Dollar. About 47% of Dollar Tree's sales in fiscal 2023 were composed of consumables (including food, health and beauty, and cleaning products), around 45% from variety items (including toys and homewares), and over 5% from seasonal items. The Dollar Tree banner sells most of its merchandise at the $1.25 price point and positions its stores in well-populated suburban markets. Conversely, Family Dollar primarily sells consumable merchandise (80% of the banner's sales) at prices below $10. About two-thirds of Family Dollar's stores are located in urban and suburban markets, with the remaining one-third located in rural areas.
<h3>Key Indicators: Dollar Tree's Financial Health</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Dollar Tree's remarkable performance in 3 months is evident. As of 31 October, 2024, the company achieved an impressive revenue growth rate of 3.46%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 3.08%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Dollar Tree's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.11%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Dollar Tree's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.02%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.38.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DLTR

A Glimpse Into The Expert Outlook On Dollar Tree Through 16 Analysts

MSGM, TC among major communication services gainer; DIS, FUBO among losers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
TruGolf Holdings (NASDAQ:<a href="https://investorplace.com/stock-quotes/trug-stock-quote/">TRUG</a>) just reported results for the fourth quarter of 2024.<ul><li>TruGolf Holdings reported earnings per share of -22 cents.</li><li>The company reported revenue of $5.12 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/trug-stock-earnings-trugolf-holdings-for-q4-of-2024/">TRUG Stock Earnings: TruGolf Holdings Reported Results for Q4 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TRUG Stock Earnings: TruGolf Holdings Reported Results for Q4 2024

TruGolf Links enters into franchise development agreement

Sees 2024 second half EBITDA greater than $500K. The company states: "The Company expects to report strong revenues for the second half of 2024 dri...

TruGolf sees 2024 second half revenue up 8%-12%

TruGolf expects 8-12% topline growth in H2

Reports Q3 revenue $6.2M vs. $3.4M last year. "This strong third quarter growth is a direct result of the significant investment we have made in ou...

TruGolf reports Q3 EPS 0c vs. ($219.38) last year

Total revenue for end of 2024 is expected to grow by 9%-13% as compared to end of 2023 levels. EBITDA for the second half of 2024 is estimated to r...

TruGolf revises FY24 outlook

TruGolf GAAP EPS of $0.00, revenue of $6.24M

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.&nbsp; 1. STOCK NEWS: Shares of Domino's Pizza (DPZ) w...

Berkshire reveals stake in Domino's, Alibaba reports mixed Q2: Morning Buzz

TruGolf (TRUG) released its newest virtual golf software, E6 APEX. The software utilizes industry-leading AI and Machine Learning powered video gam...

TruGolf announces newest virtual golf software, E6 APEX

AENT

ALHC

AMAT

AMZN

ASTS

BABA

BODI

CASI

DESP

DRCT

EVER

FLNT

FUBO

HALO

MSGM

RCAT

SEDG

SLGL

SSNLF

TRUG

TWLO

Press Releases

TRUGOLF RELEASES GROUNDBREAKING E6 APEX RANGE TRAINING SOFTWARE AND SIGNS JOE HALLETT, PGA COACH OF THE YEAR

Sports

Events

General

TruGolf to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

TruGolf Appoints Doug Bybee as Chief Revenue Officer

TruGolf Launches National Franchising Initiative with Regional Developer Model

TruGolf Holdings Signs Exclusive Licensing Deal with Golf Blueprint

TruGolf Links Signs Inaugural Franchise Development Deal with New Jersey Businessman

TruGolf Links Announces Franchise Development Agreement for Chicagoland and Northwest Indiana

TruGolf Announces Guidance for Second Half 2024

TruGolf Announces 82% YOY Third Quarter Sales Growth

TruGolf Announces Course Play for E6 APEX Virtual Golf Software

Blue Hat Interactive Entertainment Technology - Ordinary Shares

Blue Hat Interactive

DoubleDown Interactive Co., Ltd. - American Depository Shares

DoubleDown Interactive

DouYu International Holdings Limited - American Depositary Shares

DouYu Intl Hldgs

Electronic Arts

GDEV

Golden Matrix Group

GRAVITY Co., Ltd. - American depositary shares, each representing one common share.

GRAVITY Co

Gaxos.AI

HUYA Inc. American depositary shares, each representing one Class A ordinary share

HUYA

iHuman Inc. American depositary shares, each representing five Class A ordinary shares

iHuman

Motorsport Games Inc. - Class A Common Stock

Motorsport Games

PLAYSTUDIOS

NetEase, Inc. - American Depositary Shares, each representing 5 ordinary shares

NetEase

Playtika Holding

Roblox

Sea Limited American Depositary Shares, each representing one Class A Ordinary Share

Comments

TruGolf Holdings

空売り

TruGolf Holdings (NASDAQ:TRUG) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル